Resources: Page 69

Ga-68 PSMA-11 PET changes management for most patients
By Will Morton
Wednesday, November 30 | 9:30 a.m.-10:30 a.m. | W3-SSNMMI06-2 | Room S502Gallium-68 (Ga-68) prostate-specific membrane antigen (PSMA)-11 PET/CT and PET/MRI resulted in patient management changes in most clinical trial participants with prostate cancer, according to research presented in this session.
November 21, 2022
F-18 FDOPA best for imaging adrenal tumors related to MEN 2
By Will Morton
Tuesday, November 29 | 1:30 p.m.-2:00 p.m. | T6-STCE-4 | Learning Center TheaterIn this molecular imaging scientific session, researchers will make the case that F-18 fluorodopa (FDOPA) should be the radiotracer of choice among four evaluated for diagnosing adrenal gland tumors related to multiple endocrine neoplasia type 2 (MEN 2).
November 21, 2022
SSR-PET/CT outperforms biopsy for diagnosing liver NET metastases
By Will Morton
Tuesday, November 29 | 9:30 a.m.-10:30 a.m. | T3-SSNMMI05-5 | Room E351In this scientific session, a retrospective study will be presented that evaluated the accuracy of somatostatin receptor (SSR)-PET/CT for detecting liver metastases in differentiated neuroendocrine tumors (NETs).
November 21, 2022
FDG-PET/CT improves management of patients with sarcomas
By Will Morton
Sunday, November 27 | 10:30 a.m.-11:30 a.m. | S2-SSNMMI01-4 | Room E352In this scientific session, a study will be presented on the impact of F-18 FDG-PET/CT imaging on initial staging, restaging, clinical management, and outcomes for patients with soft-tissue and bone sarcomas.
November 21, 2022
FDG-PET/MRI can guide breast cancer therapy changes
By Amerigo Allegretto
Sunday, November 27 | 9:00 a.m.-9:30 a.m. | S1-STCE-3 | Learning Center TheaterIn this talk, researchers will discuss how F-18 FDG-PET/MRI leads to therapy changes in breast cancer patients with elevated pretest probability for distant metastases.
November 21, 2022
Road to RSNA 2022: Molecular Imaging Preview
By Will Morton
This year's nuclear medicine and molecular imaging program at RSNA 2022 resounds with the impact of theranostics on the lives of patients with prostate cancer, with prostate-specific membrane antigen PET imaging taking center stage. Organizers even saw fit to title one scientific session "Prostate and Theranostics Potpourri."
November 21, 2022
Susceptibility-weighted MRI shows brain changes in COVID-19 patients
By Kate Madden Yee
Susceptibility-weighted MRI reveals that patients who have recovered from COVID-19 show changes in their brains up to six months later, according to research to be presented at the upcoming RSNA meeting.
November 20, 2022
2022 11 21 04 02 4919 2022 11 21 Brain Abnormalities 20221121042148
MRI casts doubt on the benefits of taking NSAIDs for arthritis
By Kate Madden Yee
MRI has shown that taking nonsteroidal anti-inflammatory drugs (NSAIDs) for osteoarthritis in the knee joint may actually make inflammation worse, according to research to be presented at the upcoming RSNA meeting in Chicago.
November 20, 2022
2022 11 21 03 29 7185 2022 11 21 Rsna Pr Fat Pad 20221121035526
B-mode breast ultrasound can aid in predicting treatment response
By Amerigo Allegretto
Thursday, December 1 | 1:30 p.m.-2:30 p.m. | R6-SSBR11-6 | E451BB-mode breast ultrasound can aid in predicting response to neoadjuvant chemotherapy, according to this scientific presentation.
November 20, 2022
Could volume sweep imaging assist in breast cancer detection?
By Amerigo Allegretto
Thursday, December 1 | 9:30 a.m.-10:30 a.m. | R3-SSIN07-3 | S404A new system that automatically detects palpable breast lumps without the need of a sonographer or radiologist will be explained in this RSNA session.
November 20, 2022
Is MR-HIFU safe for treating patients with osteoid osteoma?
By Amerigo Allegretto
Thursday, December 1 | 8:00 a.m.-9:00 a.m. | R1-SSMK10-1 | E451AIn this presentation, research will highlight the safety and efficacy of MR-guided high-intensity focused ultrasound (MR-HIFU) when it comes to treating osteoid osteoma close to sensitive body structures.
November 20, 2022
Ultrasound molecular imaging can characterize ovarian masses
By Amerigo Allegretto
Wednesday, November 30 | 1:30 p.m.-2:30 p.m. | W6-SSOB02-6 | E353CUltrasound molecular imaging (USMI) using a clinical-grade contrast agent shows promise for characterizing ovarian masses, according to this scientific presentation.
November 20, 2022
Previous Page
Page 69 of 725
Next Page